Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

BioNeex Raises $0.5 Million Seed Round to Expand its Biopharma R&D Business Development Platform


News provided by

BioNeex, Inc.

Feb 15, 2024, 15:30 ET

Share this article

Share toX

Share this article

Share toX

Investment Led by Global Biopharma Executives as Company Adds Industry Expertise to its Advisory Board

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- BioNeex (www.bioneex.com), the biopharmaceutical industry's first research and development (R&D) business development platform, announced today it has successfully closed its $0.5 million seed round of financing oversubscribed and launched a new $6 million funding round. The BioNeex marketplace connects biotech and biopharma companies, along with venture capital investors, with the most up-to-date drug candidate information directly from drug developers to facilitate biopharma licensing, co-development partnerships and investment.

Investment in BioNeex's successful seed funding round was led by biopharma industry leaders, including former executives at Pfizer and Amgen. The funds raised will be used for product development, including to enhance the user experience for BioNeex platform members. The company is also working to improve client support and add new services on behalf of its global client base. BioNeex is already welcoming venture capital firms and family offices for its next funding round, with a goal of raising $6 million.

"We are proud to see that industry leaders with extensive experience and knowledge of the biopharmaceutical industry truly believe in the BioNeex platform as a tool to increase partnerships and investments in biopharma through one-on-one connections in the marketplace," said Dr. Smbat Rafayelyan, Founder & CEO of BioNeex. "Their investment in BioNeex will help us continue to provide new products, services and platform enhancements that improve how drug development companies, potential partners and investors interact via the BioNeex marketplace."

BioNeex's ongoing success has been led by its hands-on Advisory Board, which includes industry leaders from biopharma and venture capital firms. The advisors include a former president of Pfizer China, venture partner at Fulcrum Equity Partners, former CEO of Takeda Ventures, former managing director at Blackstone Group, former managing partner of Nextech Invest and industry leader with experience at Amgen, Johnson & Johnson and Moderna. Under their leadership, BioNeex has continued to strengthen its team and invest in both product development and market growth.

BioNeex expanded its technology expertise by adding industry leader Edgar Marukyan as its first Chief Technology Officer (CTO). Marukyan joined BioNeex from the digital marketing technology company Renderforest, where he led the creation and launch of three successful products spanning three different platforms. During his tenure, the company grew to serve more than 20 million product users, resulting in multi-million dollar revenue growth. Today, Marukyan is leading BioNeex's continued enhancement of its proprietary drug candidates listing process and searching, as well as its recommendation and matchmaking algorithms.

The BioNeex platform is a secure online marketplace serving more than 300 biotech and biopharma companies, along with venture capital firms, where companies list drug candidates available for licensing, co-development partnerships and investment. On the business development platform, companies and venture capital firms match and connect directly to discuss licensing and co-development partnerships and investment deals. BioNeex delivers the most up-to-date drug candidate information in the biopharma industry, provided directly from drug discovery and development companies. The marketplace is focused on novel drug candidates — first-in-class, best-in-class new molecular entities (NMEs) with underlying proprietary platform technologies.

About BioNeex

BioNeex is the first R&D business development platform in the biopharmaceutical industry. The platform provides a marketplace where biotech and biopharma companies, along with venture capital firms come together to directly facilitate licensing and co-development partnerships for preclinical and clinical-stage drug candidates, and investment deals. BioNeex enables potential licensing and co-development partners and investors access to the most accurate and up-to-date information from drug candidate developers, and to contact them directly. For more information, please visit: www.bioneex.com.

Media Contacts

Dr. Smbat Rafayelyan, Founder & CEO of BioNeex | 49 177 238 5727, [email protected]

Join BioNeex on social media: LinkedIn, X, YouTube.

SOURCE BioNeex, Inc.

Modal title

Biopharma R&D Business Development Platform
Biopharma R&D Business Development Platform
Dr. Smbat Rafayelyan, Founder & CEO, BioNeex
Dr. Smbat Rafayelyan, Founder & CEO, BioNeex
Biopharma R&D Business Development Platform Dr. Smbat Rafayelyan, Founder & CEO, BioNeex

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.